XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Contingent Consideration (Details)

Commitments and Contingencies - Contingent Consideration (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 21, 2023	Mar. 31, 2023	Mar. 29, 2023	Dec. 31, 2022	Feb. 25, 2019
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs	$ 1,000	$ 1,000	$ 1,000	$ 1,000				$ 75
Receipts under RPAs, AAAs and CPPAs				2,934
Changes in estimated fair value of contingent consideration				75
LadRx
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs					$ 1,000
Changes in estimated fair value of contingent consideration	0
Aronora, Kuros, Affitech, ObsEva, and Merck KGaA
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs	0	0	0	0
Royalty Purchase Agreement \| LadRx
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs					$ 1,000
Changes in estimated fair value of contingent consideration				0
Royalty Purchase Agreement \| Bioasis
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs	0	0	0	0					$ 75
Commercial Payment Purchase Agreement \| Aptevo
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs	$ 0	0	0	0		$ 50	$ 50
Payment for contingent consideration under CPPA				$ 50
Commercial Payment Purchase Agreement \| Aptevo \| Minimum
Commitments And Contingencies
Receipts under RPAs, AAAs and CPPAs			$ 500
Commercial Payment Purchase Agreement \| Medexus
Commitments And Contingencies
Receipts under RPAs, AAAs and CPPAs		$ 600